Questions Answered

Reference library covering deals, PBM negotiations, drug pricing policy, and the structural mechanics behind pharmaceutical markets.

54 canonical answers · 9 categories

General

• What does RxInsider cover?
• How does RxInsider source its deal intelligence?
• Who is RxInsider written for?
• What makes RxInsider different from other pharma publications?
• How is RxInsider different from RxNews?
• Does RxInsider accept sponsored content or advertiser influence?
• What is the Deal Tracker?
• How often is the Deal Tracker updated?
• How often is content published?
• Who is the intended audience for RxInsider?
• Does RxInsider accept sponsored content?

Data & Methods

• Where does NADAC data come from and how reliable is it?
• How should I interpret biosimilar market share data?
• What does the FDA drug shortage database actually track?

Deals & M&A

• What is the difference between M&A and licensing deals?
• What is the typical structure of a pharma M&A deal?
• How do earnout provisions work in pharma licensing deals?
• What triggers antitrust review in pharma M&A?
• How are pharma deal valuations typically calculated?
• What is the significance of contingent value rights in acquisitions?
• Why is Eli Lilly spending $3.8 billion on vaccine developers?

Economics

• What does gross-to-net mean in pharma?
• What is the gross-to-net bubble and why does it matter?
• How do pharma companies report rebate accruals in earnings?
• What drives specialty drug pricing in the US?
• How does the 340B program affect manufacturer economics?
• What are channel economics in pharmaceutical distribution?

PBM Negotiations

• How do PBM formulary negotiations work?
• How do PBM rebate negotiations actually work?
• What is the difference between WAC, AWP, and NADAC?
• How does formulary tier placement affect patient access?
• What is step therapy and how do PBMs use it?
• How do 340B contract pharmacies affect PBM negotiations?

People

• How do executive changes at pharma companies signal strategy shifts?
• What is the chief pharmacy officer role in health systems?
• How do activist investors change pharma company strategy?

Pipeline

• What is the typical FDA approval timeline for a new drug?
• How does biosimilar interchangeability differ from FDA approval?
• What are the key late-stage pipeline catalysts to watch?
• What is the current probability of success from Phase 1 to approval?
• How do accelerated approval pathways affect pipeline strategy?

Policy & Regulation

• What is the IRA drug price negotiation program?
• What drugs are included in IRA Medicare price negotiation?
• How does the IRA inflation rebate penalty work?
• What is the current status of state PBM reform legislation?
• How does the FTC PBM investigation affect the industry?
• What is the Medicare Part D redesign under the IRA?
• What is Eli Lilly alleging in its $200M Trulicity rebate fraud lawsuit?

Theweek

• How is the Weekly Pharma Roundup different from daily news coverage?
• What criteria determine which stories make the weekly roundup?
• Why did the FDA delay its decision on AstraZeneca’s camizestrant?
• Why did the FDA delay its decision on AstraZeneca’s oral SERD camizestrant?
• How is Astellas addressing Xtandi patent loss while Moderna’s flu shot nears FDA review?
• What major FDA approvals and leadership changes occurred in pharma this week?